We are excited to announce that Precision Value & Health, a business unit of Precision Medicine Group, has been ranked #6 in MM&M magazine’s Agency Top 100 list! With a 10.6% increase in revenue from the previous year, they are continuing to add talent and services–partnering with pharmaceutical and life sciences companies to ensure patient access to life-changing therapies. (more…)
EXPANDED EMPHASIS ON INTERPRETING THE SCIENCE OF COMPLEX MEDICAL INNOVATIONS
BOLSTERS PRECISION’S CAPABILITIES TO SUPPORT COMMERCIAL AND R&D CLIENT BASE
Bethesda, MD – Tuesday, July 10, 2018 – Precision Medicine Group, LLC., announced it is acquiring ETHOS Health Communications, a Pennsylvania-based agency specializing in the interpretation and communication of innovative medical science. The acquisition of ETHOS, which informs physicians, providers and other stakeholders through medical affairs- and marketing-based scientific content, allows Precision to offer its clients a significantly expanded cadre of doctoral-level science and medical communications specialists.
PHE in Health Affairs, Value in Health,and more…
Health Affairs Blog Article on Patient-Centered Formularies
PHE Senior Director Jason Shafrin and Director Mark Linthicum published an article on the importance of accounting for patient heterogeneity in formulary design and the potential use of tools to help payers understand and assess patient-centered value.
—
Health Affairs Blog Article on Components of Value Frameworks
PHE Scientific Advisor Anupam Jena, along with Lauren Neves and Randy Burkholder, published an article in the Health Affairs Blog on April 16, 2018, on the importance of capturing comprehensive components of the value of medical innovations in value frameworks.
—
Value in Health Study on the Impact of Improved Mobility
PHE researchers quantified the impact of improved mobility on using PHE’s proprietary microsimulation THEMIS, finding that improvements in mobility are likely to lead to significant reductions in medical expenditures and nursing home utilization and significant increases in employment.
—
Pharmaceutical Executive Article on the Role of Pharmaceutical Companies in Value Assessment
PHE’s Ross Maclean and Jeroen Jansen published an article in Pharmaceutical Executiveon the role of pharmaceutical companies in conducting transparent and relevant evaluations of value, advocating an open-source approach to conducting cost-effectiveness evaluations.
Transparent and Relevant Evaluations of Value: An Active Role for Pharma
Precision is pleased to announce that Dan Renick has been named as one of PM360 Magazine’s annual ELITE Award winners. Congratulations, Dan! (more…)
Addition of London-based multichannel healthcare agency complements and strategically expands existing global expertise and capabilities
BOSTON, MA – April 24, 2018 – precisioneffect, the healthcare advertising agency dedicated to working with companies that seek to change the standard of care, today announced it is acquiring Big Pink, a leading European multichannel marketing healthcare agency recognized for providing strategically designed and creatively delivered campaigns to the pharmaceutical industry worldwide. The acquisition marks an important expansion of precisioneffect’s global footprint and employee base, and positions the company to provide its clients with additional value through enhanced services and expertise. (more…)
TAPPING FORMER PAYER DECISION MAKERS BOYCE, HONCZ AND OYEKAN
BRINGS UNRIVALED INSIGHTS TO CLIENTS
APRIL 18th, 2018 – New York, NY – Precision for Value, the market leader in supporting global pharmaceutical and life sciences companies in demonstrating the value and outcomes of innovative medical products, today announced significant additions to its Payer Strategy Team with the hiring of former payer executives Marylou Buyse, Joe Honcz, and Elizabeth Oyekan. (more…)
Precision’s All Access is our bimonthly newsletter with original content written by our payer experts for market access leaders. (more…)
In an interview with KNect365, Precision Oncology’s Dr. Tandy Tipps, VP, Oncology Site Network, tells you how to match the right sites to the right trials and enable the opportunities of precision oncology trials. (more…)
In an article in Pharmaceutical Commerce, Precision’s Dominic Galante and Maureen Hennessey stress the importance of patient support services among pharma companies, payers, and providers. (more…)
In part 2 of their Guest Commentary series, Precision’s Todd Edgar, Alex Grosvenor, and Kellie Rademacher highlight the takeaways of the NOR-SWITCH trial and how the EU’s view of biosimilars as therapeutic alternatives is influencing US policy. (more…)